Experts in Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Experts in Excipients

MEGGLE Excipients & Technology is a global leader in the manufacture of lactose for the pharmaceutical industry.  Supporting supply chain security with manufacturing facilities in Europe and North America, MEGGLE offers a broad product portfolio of lactose excipients, co-processed technologies and excipient contract manufacturing. 


MEGGLE is a pioneer in co-processing technologies that allow simple, robust formulation development and manufacture.  Through co-processing, MEGGLE developed highly functional excipients possessing unique qualities for directly compressible immediate and sustained release pharmaceutical solid dosage forms. 
As a family owned, German company, MEGGLE has proudly produced quality products for consumers and industry for four generations.

                MEGGLE Excipients & Technologies serves the pharmaceutical and biotechnology markets with a global network of offices and authorized agents. As an innovator in co-processed technology, MEGGLE also provides contract manufacturing services to several other global excipient companies.
Our broad portfolio of products, multiple manufacturing locations, technical centers in major markets, and innovative technologies, make MEGGLE the preferred supplier and valued partner by large and small pharmaceutical product manufacturers.      

MEGGLE Excipients & Technologies excipient products:

  • Lactose monohydrate
  • Anhydrous Lactose
  • Co-Processed Excipients
  • Lactose for Inhalation
  • Lactose for lyophilization and parenteral applications
  • Customized lactose products

MEGGLE Gruppe Wasserburg

Service.pharma@meggle.de
www.meggle-pharma.com
Phone +49 8071 73 476
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here